Charles Morris joined Neuraxpharm as Head of Mergers & Acquisitions in January 2022. Charles is a seasoned M&A professional with 20 years of experience in investment banking and corporate M&A in the pharmaceutical industry, across multiple geographies, including the US, Germany and Spain.
Before joining Neuraxpharm, Charles was Global Head of M&A and Corporate Development at Almirall (2019-2021) and prior to this he was Vice President, Head of M&A, Pharma General Medicine & Animal Health at Bayer AG (2010-2019). Earlier in his career, Charles worked in investment banking and equity research for Bank of America, Merrill Lynch and Molecular Securities in New York.
Charles holds an MBA from Columbia Business School (USA) and an undergraduate degree in Economics and Political Science from Emory University (USA).
Join our mailing list
Get the latest updates from the Neuraxpharm.